Home/Filings/4/0001062993-24-008547
4//SEC Filing

Blue Horizon Enterprise Ltd 4

Accession 0001062993-24-008547

CIK 0001623526other

Filed

Apr 17, 8:00 PM ET

Accepted

Apr 18, 4:16 PM ET

Size

10.8 KB

Accession

0001062993-24-008547

Insider Transaction Report

Form 4
Period: 2024-04-17
Transactions
  • Sale

    Common Stock

    2024-04-17$11.60/sh3,600,000$41,760,00010,843,681 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2024-04-17$11.60/sh3,600,000$41,760,00010,843,681 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2024-04-17$11.60/sh3,600,000$41,760,00010,843,681 total(indirect: See Footnote)
Transactions
  • Sale

    Common Stock

    2024-04-17$11.60/sh3,600,000$41,760,00010,843,681 total(indirect: See Footnote)
Footnotes (1)
  • [F1]Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 6,905,121 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 3,938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.

Issuer

Stoke Therapeutics, Inc.

CIK 0001623526

Entity typeother
IncorporatedVirgin Islands, British

Related Parties

1
  • filerCIK 0001869057

Filing Metadata

Form type
4
Filed
Apr 17, 8:00 PM ET
Accepted
Apr 18, 4:16 PM ET
Size
10.8 KB